Next-generation strategies for gene-targeted therapies of central nervous system disorders: A workshop summary

The National Institute of Neurological Disorders and Stroke (NINDS) held a workshop titled Next generation strategies for gene-targeted therapies of central nervous system (CNS) disorders in September 2019 in Bethesda, MD, USA. The meeting brought together a multi-disciplinary group of experts in the field of CNS-directed gene-targeted therapy delivery from academia, industry, advocacy, and the government. The group was charged with identifying the key challenges and gaps in this evolving field, as well as suggesting potential solutions. The workshop was divided into four sessions: (1) control of level and location, (2) improving delivery and distribution, (3) enhancing models and manufacturing, and (4) impacting patients. Prior to the workshop, NINDS established working groups of key opinion leaders (KOLs) for each session. In pre-meeting teleconferences, KOLs were tasked with identifying the research gaps and key obstacles that delay and/or prevent gene-targeted therapies to move into the clinic. This approach allowed for the workshop to begin with problem solving discussions and strategy development, as the key issues had been established. The overall purpose of the workshop was to consider knowledge gaps and potential strategies to inform the community around CNS gene-targeted therapies, including but not limited to researchers and funders.

Automated summary

NINDS organized a workshop on gene-targeted therapies for CNS disorders, bringing together experts from various fields to identify challenges and propose solutions. Prior to the workshop, key obstacles and research gaps were identified through pre-meeting teleconferences, allowing for problem-solving discussions and strategy development at the workshop.